Zoetis Inc. (ZTS) Stock
ZTS Key Statistics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
CEO: Kristin C. Peck. Company website
ZTS — Frequently Asked Questions
What is the ZTS stock price today?
Zoetis Inc. (ZTS) trades at $71.45, down 2.15% on the day, as of Sep 20, 2026 14:59 UTC.
What is Zoetis Inc.'s market cap?
Zoetis Inc. has a market capitalisation of $29.95B, calculated from the live ZTS share price and shares outstanding.
What is the P/E ratio of ZTS?
ZTS trades at a trailing P/E of 11.77, from earnings per share of $6.07 over the last twelve months.
How much revenue does Zoetis Inc. make?
Zoetis Inc. generated revenue of $9.52B over the trailing twelve months, which puts the stock at 3.15 times sales.
Does ZTS pay a dividend?
Yes. Zoetis Inc. pays a dividend yielding 1.61% on the current share price.
What is the 52-week range for ZTS?
ZTS has traded between $71.00 and $149.75 over the past 52 weeks, and the last price is 52.3% below that high.
Is Zoetis Inc. profitable?
Yes. Zoetis Inc. keeps 27.49% of revenue as net income over the trailing twelve months.
What is the analyst price target for ZTS?
Wall Street analysts rate ZTS Hold, with an average price target of $87.33, 22.2% above the current price.
What sector is Zoetis Inc. in?
Zoetis Inc. is classified under the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is domiciled in US.
Who is the CEO of Zoetis Inc.?
Kristin C. Peck is the chief executive of Zoetis Inc., which employs 14,500 people.
Where can I track ZTS in real time?
QFI Terminal shows ZTS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ZTS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ZTS in Terminal See plans